Re: Navelbine & Herceptin Not Working
 

Karen,

Y-90 looks really good. I'm sending you good vibes.

Ann Surg Oncol. 2014 Apr;21(4):1296-303. doi: 10.1245/s10434-013-3436-1. Epub 2013 Dec 15.
Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.

Saxena A1, Kapoor J, Meteling B, Morris DL, Bester L.
Author information

• 1Department of Interventional Radiology, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia, akshat16187@gmail.com.

Abstract

INTRODUCTION:

There are a paucity of data on the treatment of unresectable, chemoresistant breast cancer liver metastases (BRCLM) with yttrium-90 (Y90) radioembolization.
METHODS:

Forty patients underwent resin-based Y90 radioembolization for unresectable, chemoresistant BRCLM between 2006 and 2012 in a single institution. All patients were followed up with imaging studies at regular intervals as clinically indicated until death. Radiologic response was evaluated with the Response Criteria in Solid Tumors criteria. Clinical toxicities were prospectively recorded as per the National Cancer Institute Common Toxicity Criteria. Survival was calculated by the Kaplan-Meier method and potential prognostic variables were identified on univariate and multivariate analysis.
RESULTS:

Follow-up was complete in all patients. The median follow-up was 11.2 (range 0.6-30.5) months and the median survival after Y90 radioembolization was 13.6 months, with a 24-month survival of 39 %. On imaging follow-up of 38 patients who survived beyond 1 month of treatment, a complete response (CR) to treatment was observed in two patients (5 %), partial response (PR) in 10 patients (26 %), stable disease (SD) in 15 patients (39 %), and progressive disease (PD) in 11 patients (29 %). Two factors were associated with an improved survival on multivariate analysis: CR/PR to treatment (vs. SD vs. PD; p < 0.001) and chemotherapy after radioembolization (vs. no chemotherapy; p = 0.004). Sixteen patients (40 %) developed clinical toxicity after treatment; all complications were minor grade I/II and resolved without active intervention.
CONCLUSION:

This study provides supportive evidence of the safety and efficacy on Y90 radioembolization for the treatment of unresectable, chemoresistant BRCLM. Further prospective investigation is required to assess the suitability of this treatment in this population.

Re: Navelbine & Herceptin Not Working
 

Good luck with the new regime, sounds promising! Hope the PET looks good

Re: Navelbine & Herceptin Not Working
 

Dear Karen, I have been thinking about you, I told my daughter about how
extraordinary and fabulous person you are. She has seen your pictures on
Facebook and totally agrees with me about how beautiful you are.

Please keep us posted after Saturday's scans. In the meantime enjoy your
hubby and daughter - they are so precious!

Hang in there my lovely friend. Love you. Hugs and more hugs.

Adriana